论文部分内容阅读
目的:评价二甲双胍联合炔雌醇环丙孕酮治疗多囊卵巢综合征(PCOS)的疗效及安全性。方法:140例PCOS患者随机分为对照组和观察组各70例。对照组口服炔雌醇环丙孕酮,观察组口服炔雌醇环丙孕酮和二甲双胍。疗程3个月。比较治疗前后两组患者的体重指数(BMI)、腰臀比(WHR)、空腹血糖(FBG)、空腹胰岛素(FINS)、激素水平变化,记录两组患者药品不良反应及排卵率、妊娠率。结果:治疗后,两组促黄体激素(LH)、泌乳素(PRL)、睾酮(T)、平均卵泡数和平均卵巢体积均明显降低(P<0.05),对照组WHR增高(P<0.05),观察组子宫内膜厚度降低(P<0.05);且观察组WHR、FINS、LH、T、子宫内膜厚度、平均卵泡数和平均卵巢体积明显低于对照组(P<0.05)。两组BMI、FBG、药品不良反应发生率及排卵率、妊娠率等相近(P>0.05)。结论:二甲双胍联合炔雌醇环丙孕酮疗效优于单用炔雌醇环丙孕酮,更适合PCOS患者。
Objective: To evaluate the efficacy and safety of metformin combined with ethinyl estradiol cyproterone in the treatment of polycystic ovary syndrome (PCOS). Methods: 140 patients with PCOS were randomly divided into control group and observation group of 70 cases. In the control group, ethinyl estradiol and cyproterone were orally administered, and ethinyl estradiol, cyproterone and metformin were orally administered in the observation group. Course of 3 months. Body mass index (BMI), WHR, FBG, FINS and hormone levels were compared between the two groups before and after treatment. Adverse reactions, ovulation rate and pregnancy rate were recorded in both groups. Results: After treatment, the levels of LH, PRL, T and average ovarian volume in both groups were significantly decreased (P <0.05), while the WHR in the control group was higher (P <0.05) (P <0.05). The WHR, FINS, LH, T, endometrial thickness, average number of follicles and average ovarian volume in the observation group were significantly lower than those in the control group (P <0.05). Two groups of BMI, FBG, the incidence of adverse drug reactions and ovulation, pregnancy rates were similar (P> 0.05). CONCLUSION: Metformin combined with ethinyl estradiol cyproterone is superior to ethinyl estradiol cyproterone alone and is more suitable for patients with PCOS.